Bethlehem, Penn.-based B. Braun did not release any details of the acquisition, and has not revealed how it plans to integrate the business into its existing product lines.
“We are pleased to add the Streamline bloodline to our dialysis product portfolio. Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog hemodialysis machine and the Diacap Pro dialyzer,” B. Braun VP Sam Amory said in a press release.
The acquisition is contingent upon the closure of Fresenius Medical Care‘s (NYSE:FMS; ETR:FRE) $2 billion acquisition of NxStage, B. Braun said. The company is hopeful that the acquisition will close this year.
The divestiture could mean that the $2 billion sale could be moving closer to completion. Last October, Fresenius and NxStage received a request from the US Federal Trade Commission asking for more information on the acquisition.
The companies originally announced the acquisition last August, with Fresenius looking to pay $30 per share for Lawrence, Mass.-based home hemodialysis developer NxStage.